MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
Article in Clinical Epigenetics (January 2024)
The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.
Article in Clinical Epigenetics (January 2024)
Article in Oncogene (November 2023)
Article in British Journal of Cancer (October 2023)